Welcome to our dedicated page for Prothena SEC filings (Ticker: PRTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotechnology filing packed with clinical data tables and milestone accounting notes can feel daunting. Prothena’s SEC documents are no exception—trial updates, R&D burn rates, and partnership revenue estimates are buried across hundreds of pages. If you have ever searched for “Prothena SEC filings explained simply” or struggled to trace insider sales before a data readout, you know the challenge.
Stock Titan solves that problem. Our AI-powered summaries translate Prothena quarterly earnings report 10-Q filing details into clear language, flag key cash-runway metrics, and link every risk factor to its clinical program. Need “Prothena insider trading Form 4 transactions” or “Prothena executive stock transactions Form 4” alerts? We deliver them in real-time, alongside expert context. From a single dashboard you’ll also find the Prothena annual report 10-K simplified, “Prothena proxy statement executive compensation” tables highlighted, and each “Prothena 8-K material events explained” within minutes of hitting EDGAR.
Whether you monitor biologics pipeline milestones or compare quarter-over-quarter R&D expenses, our platform keeps every document at your fingertips:
- Real-time updates the moment Prothena Form 4 insider transactions hit the tape
- AI summaries that clarify immunotherapy terminology and clinical-stage accounting
- Side-by-side “Prothena earnings report filing analysis” for trend spotting
Todd W. Fennell filed an amendment to a Schedule 13G disclosing beneficial ownership of 4,350,846 ordinary shares of Prothena Corporation plc, representing approximately 8.08% of the 53,826,982 shares outstanding. The reported holdings consist of 40,000 shares held by an irrevocable gift trust and 4,310,846 shares held by multiple grantor retained annuity trusts, for which Mr. Fennell serves as independent trustee.
The filing shows shared voting and shared dispositive power over all reported shares and includes a certification that the securities are not held to change or influence control of the issuer. This disclosure provides investors a clear view of a materially significant, statedly passive stake in PRTA and identifies the legal vehicles through which the interest is held.
Prothena Corporation plc has filed a registration statement to register ordinary shares issuable under its Prothena Corporation plc 2018 Long Term Incentive Plan, as amended. The filing incorporates by reference the companys existing public reports, including the Annual Report for the year ended December 31, 2024 and recent quarterly reports, to supply the required disclosure. The companys Constitution, as publicly filed, provides for indemnification of directors and certain executives to the extent permitted by Irish law, and the company maintains insurance and indemnification agreements for officers and directors. The exhibit list documents the Plan and multiple amendments (First through Sixth) and includes legal and auditor consents.
On 28 Jul 2025, Prothena Corporation plc (PRTA) filed a Form 4 reporting that its Chief Scientific Officer, Dr. Wagner M. Zago, acquired 85,000 ordinary shares of the company. The transaction was coded “A,” indicating an acquisition that was not purchased for cash (reported price $0), consistent with an equity award or similar grant. Following the transaction, Dr. Zago’s direct beneficial ownership totals 85,000 shares. No derivative securities were reported, and there were no dispositions. The filing was signed by Michael J. Malecek under power of attorney on 30 Jul 2025.
FAQ
What is the current stock price of Prothena (PRTA)?
What is the market cap of Prothena (PRTA)?
